A5091271730- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Prostate Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Urologic and reproductive health conditions
- Renal cell carcinoma treatment
- Medical Imaging Techniques and Applications
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Myasthenia Gravis and Thymoma
- Hormonal and reproductive studies
- Kidney Stones and Urolithiasis Treatments
- Adrenal and Paraganglionic Tumors
- Pituitary Gland Disorders and Treatments
- Radiation Dose and Imaging
- Genital Health and Disease
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Neurofibromatosis and Schwannoma Cases
- Hepatocellular Carcinoma Treatment and Prognosis
- Adrenal Hormones and Disorders
Post Graduate Institute of Medical Education and Research
2021-2025
Jawaharlal Institute of Post Graduate Medical Education and Research
2024
<sup>177</sup>Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant with radiosensitizing low-dose capecitabine to be effective in NETs. However, this not been validated prospective randomized-controlled trials. <b>Methods:</b> In investigator-initiated, parallel-group, open-label, phase 2 trial, patients GEP-NETs, having progressive...
Multiple endocrine neoplasia (MEN) 1 syndrome may present with either of any or all neuroendocrine tumors (NETs), parathyroid and pituitary adenoma. There is a paucity data on the intronic exonic mutations in MEN1 gene associated syndrome. We an interesting study mother-daughter duo who had similar lesions distribution metastatic NET underwent genetic analysis to reveal rare mutation both first-degree relatives presented without other syndromic manifestation Both patients received peptide...
Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of therapeutic use 177 Lu-PSMA-617 in metastatic castrate-resistant cancer. However, PSMA is also expressed neovasculature other solid tumors, such as lung and renal cancer, making theranostic potential worth exploring this setting. Here a case an 83-year-old man with advanced non–small cell where was explored using dosimetric analysis.
Many benign bone lesions mimic skeletal metastases from thyroid cancer on imaging and even may have high metabolic uptake 18F-FDG PET/CT. It becomes crucial to distinguish these hypermetabolic (benign vs. metastasis), especially in patients with thyroglobulin elevation negative iodine scan. The index case describes a patient having scan aneurysmal cyst mimicking metastasis.
Carotid body tumor (CBT) is the most common head and neck paraganglioma with very rare occurrence of distant metastases. The widespread metastases in have limited treatment options, peptide receptor radionuclide therapy (PRRT) being an effective somatostatin receptor-expressing lesions. Here a case 45-year-old woman metastatic CBT who showed excellent response initially to 177Lu-DOTATATE PRRT, but presented later wheel-chair bound condition lesions spinal cord compression at multiple levels,...
Purpose: Peptide receptor radionuclide therapy (PRRT) is recommended and approved in advanced neuroendocrine tumors (NETs). There a lack of data on the utility PRRT multiple endocrine neoplasia (MEN) syndrome. This study explores MEN syndrome patients with inoperable/metastatic NETs. Methods: A single-center retrospective analysis NETs referred for was done. Upto 4 cycles 177 Lu-DOTATATE (5.5–7.4 GBq/cycle) were administered every 8–12 weeks. Treatment-related adverse events assessed using...
177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) has shown positive survival outcomes in metastatic castration-resistant prostate cancer. However, there are limited data the hormone-sensitive setting. Here, CONSOLIDATE trial (177Lu-PSMA-617 Consolidation Therapy After Docetaxel Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer), we intended to evaluate role of 177Lu-PSMA-617 as consolidation therapy for residual disease after chemohormonal...
Abstract Peptide receptor radionuclide therapy (PRRT) has shown to be effective and safe in metastatic gastroenteropancreatic nongastroenteropancreatic neuroendocrine tumors. However, the selection criteria for PRRT are restricted patients with good performance status (Eastern Cooperative Oncology Group score ≤2 or Karnofsky ≥60). This denies many adequate somatostatin expression biochemical profiles from beneficial effects of on quality life, daily function, overall survival. The 2 cases...
This single-center retrospective study explores the safety and efficacy of 177 Lu-DOTATATE in children young adult population with metastatic/inoperable neuroendocrine tumors (NETs).
5095 Background: De-novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC) presents a therapeutic challenge with dismal five-year survival rate. Till recently, androgen deprivation therapy (ADT) docetaxel had been the standard-of-care for such patients. Nevertheless, substantial proportion of patients continue to harbour residual disease after completion docetaxel. 177 Lu-PSMA-617 has shown positive outcomes in castrate-resistant setting. Here, we intended evaluate role...
Genomic defects in DNA-damage repair (DDR) mechanisms have been proposed to affect the radiosensitivity of prostate cancers. In this study, we intended evaluate prevalence genetic alterations a cohort metastatic castration-resistant cancer (mCRPC) patients undergoing radioligand therapy (RLT) with prostate-specific membrane antigen (PSMA)-inhibitors as well impact such mutations on treatment outcomes.Data consecutive mCRPC from 2017 2021 who were treated PSMA-RLT and underwent...
Abstract The occurrence of cutaneous metastases in prostate cancer is exceedingly rare. Many benign lesions and nonprostatic cancers can express the prostate-specific membrane antigen (PSMA). They potentially mimic metastasis lead to misinterpretation PSMA PET/CT findings. Additionally, it has significant management prognostic implications. We present a rare case an 88-year-old man with metastatic castration-resistant who showed PSMA-expressing subcutaneous nodule scalp on 18 F-PSMA-1007...
BACKGROUND: Body mass index (BMI) may not accurately predict cardiometabolic risk due to confounders like age, gender, relatively high lean mass, and the “thin-fat phenotype” prevalent in south Asian populations. Fat-to-lean ratio (FTLM), which assesses balance between fat body provide a more complete assessment of health. MATERIALS AND METHODS: This cross-sectional analytical study investigated relationship FTLM ratio, BMI, heart rate variability (HRV) apparently healthy male adults. 88...
Background and purpose: Urinary Citrate is an inhibitor of Calcium oxalate stone formation. It reabsorbed in the proximal kidney through sodium dicarboxylate co-transporters (NaDC-1, NaDC-3) present renal tubular epithelium. Lithium (Li) a known potent these transporters. We investigated effect lithium carbonate (LiC) citrate (LiCit) regulating urinary levels preventing nephrolithiasis (NL) rat model. Experimental approach: took 220 Wistar rats induced 130 them by administering high doses 5%...
Abstract Androgen deprivation therapy plays an integral role in the treatment algorithm of advanced prostate cancer. Enzalutamide has shown great benefit castrate-sensitive as well resistant Few studies have that enzalutamide can potentially increase PSMA expression on 68 Ga-PSMA-11 PET/CT imaging patients with metastatic castrate-resistant We present interesting case where addition short course resulted increased localization 177 Lu-PSMA-617 lesions posttherapy scan pointing to added RLT.
Abstract Various systemic treatment options are available for advanced pancreatic neuroendocrine tumors (NETs); however, individual may be suboptimally effective. Sunitinib inhibits multiple kinases and signaling pathways with delay in tumor growth, whereas peptide radioreceptor therapy (PRRT) delivers targeted radiation to the NETs. There is a dearth of literature on combined or tandem use these modalities. We present case 40-year-old man NET where PRRT sunitinib as monotherapy had...
177 Lu-PSMA radioligand therapy (RLT) has shown very encouraging results in metastatic castrate-resistant prostate cancer (mCRPC) patients with acceptable adverse events. The events of RLT are mainly limited to salivary glands and kidneys. However, there is dearth available data transplanted kidney mCRPC. Here a case 68-year-old mCRPC patient history renal transplant who underwent 4 cycles Lu-PSMA-617 (~7.4 GBq/cycle). Posttherapy serum creatinine glomerular filtration rate remained stable...
To evaluate the diagnostic utility of 68 Ga-Pentixafor PET/CT for in vivo imaging CXCR4 receptors soft tissue/bone sarcoma.
Gastrinomas with predilection for the adult male population are located in gastrinoma triangle (>90%). Primary hepatic especially pediatric is very rare. Peptide receptor radionuclide therapy has shown benefit metastatic gastroenteropancreatic neuroendocrine tumors (NETs) an increasing interest expanding its role as neoadjuvant treatment modality to improve surgical candidature inoperable NETs. There currently no literature supporting NET patients. We present a rare case of young boy primary...